Despite recent share price increase, long-term returns remain poor. The company's performance over the last year indicates unresolved challenges, with a loss of 6.7%, worse than the annualised loss of 3% over the last half decade.
Investors expect the company to continue to outperform, supporting the high P/E. Shareholders are confident about future earnings, providing robust support to the share price. Thorough analysis of balance sheets and risk factors is recommended.
石四藥集團股票討論區
暫無評論